Seehra Jasbir
SEC CIK 1732369 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| KROS | Keros Therapeutics, Inc. | CEO, Dir | 440.7K | — | $113.4K | 6 | 2022-06-09 | 2026-04-02 |
Most active insiders at KROS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Schneeberger Daniel | 10% | — | $95.66M |
| 2 | Pontifax (China) IV L.P. | 10% | — | $84.98M |
| 3 | Cho Esther | SVP, GC | — | $123.7K |
| 4 | Seehra Jasbir | CEO, Dir | — | $113.4K |
| 5 | Lerner Lorena Raquel | CSO | — | $100.0K |
| 6 | Regnante Keith | CFO | — | $77.5K |
| 7 | BIENAIME JEAN JACQUES | Dir | $75.8K | — |
| 8 | Knowles Julius | Dir | — | $28.2K |
| 9 | Farzan Nima | Dir | — | $28.2K |
| 10 | Seth Alpna | Dir | — | $28.1K |
Transactions 6
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-04-06 16:15 | 2026-04-02 | KROS | Keros Therapeutics, Inc. | Seehra Jasbir | CEO, Dir | M - OptEx | $0.3 | +55.0K | 440.7K | +14% | +$16.5K |
| 2026-02-20 | 2026-02-19 | KROS | Keros Therapeutics, Inc. | Seehra Jasbir | CEO, Dir | S - Sale | $16.17 | -7,015 | 385.7K | -2% | -$113.4K | |
| 2025-09-05 | 2025-09-03 | KROS | Keros Therapeutics, Inc. | Seehra Jasbir | CEO, Dir | A - Grant | $0.00 | +90.5K | 392.7K | +30% | $0 | |
| D | 2025-04-07 | 2025-04-04 | KROS | Keros Therapeutics, Inc. | Seehra Jasbir | CEO, Dir | M - OptEx | $0.3 | +49.4K | 302.2K | +20% | +$14.8K |
| D | 2023-04-11 | 2023-04-08 | KROS | Keros Therapeutics, Inc. | Seehra Jasbir | CEO, Dir | M - OptEx | $0.48 | +4,000 | 252.9K | +2% | +$1,920 |
| D | 2022-06-10 | 2022-06-09 | KROS | Keros Therapeutics, Inc. | Seehra Jasbir | CEO, Dir | M - OptEx | $0.3 | +5,000 | 248.9K | +2% | +$1,500 |
Purchase Sale Sale after option exercise All abbreviations